Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulvestrant and Bevacizumab in Metastatic Breast Cancer
NCT00423917Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Aug 2007
- Primary completion
- Feb 2009
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of fulvestrant, bevacizumab in breast cancer, sponsored by Cancer and Leukemia Group B. Started Aug 2007; status: completed.
02
Drugs
fulvestrantbevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00423917.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00423917.